CNS Pharmaceuticals, Inc.
CNSP
$6.12
-$0.42-6.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.78% | -35.41% | 43.34% | -121.51% | 28.60% |
| Total Depreciation and Amortization | 0.00% | 10.00% | 25.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.06% | -51.96% | -85.04% | 270.51% | 15.59% |
| Change in Net Operating Assets | -400.35% | 141.06% | -17.57% | -419.68% | 332.80% |
| Cash from Operations | -64.82% | 40.74% | 19.55% | -312.02% | 48.30% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.30% | -178.53% | 66.12% | -2.45% | -2.51% |
| Issuance of Common Stock | -50.02% | 80.50% | -59.69% | 410.15% | -31.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 8,920.00% | 75.00% | -138.10% | -- |
| Cash from Financing | -54.97% | 98.02% | -59.59% | 427.85% | -32.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.93% | 1,387.12% | -109.33% | 710.53% | 153.77% |